SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with severe rare diseases and cancer. Founded in 2017 as a spinout from Pfizer, the company is dedicated to applying precision medicine approaches to areas of high unmet medical need, particularly in oncology and genetically defined diseases. Its mission centers on advancing innovative treatments that can meaningfully improve outcomes for patients with limited therapeutic options.
Headquartered in Stamford, Connecticut, SpringWorks has built a portfolio of targeted therapies designed to address molecular drivers of disease. The company gained significant recognition with the FDA approval of OGSIVEO (nirogacestat) in 2023 for the treatment of adults with desmoid tumors, marking the first approved therapy for this rare condition. With several additional pipeline programs in oncology and rare diseases, SpringWorks has established a strong reputation in the biotechnology sector and continues to expand through research partnerships, clinical development programs, and commercialization efforts.
